New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 9, Issue 7, Pages 2222
Publisher
MDPI AG
Online
2020-07-14
DOI
10.3390/jcm9072222
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New treatments in spinal muscular atrophy: an overview of currently available data
- (2020) Sithara Ramdas et al. EXPERT OPINION ON PHARMACOTHERAPY
- Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients
- (2020) Irene Faravelli et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cerebrospinal fluid proteomic profiling in nusinersen‐treated patients with spinal muscular atrophy
- (2020) Tobias Kessler et al. JOURNAL OF NEUROCHEMISTRY
- Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019
- (2020) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Overturning the Paradigm of Spinal Muscular Atrophy as just a Motor Neuron Disease
- (2020) Crystal Jing Jing Yeo et al. PEDIATRIC NEUROLOGY
- Will the US$5 million onasemnogene abeparvosec treatment for spinal muscular atrophy represent ‘value for money’ for the NHS? A rapid inquiry into suggestions that it may be cost-effective
- (2020) Martin Connock et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
- (2020) Tai-Heng Chen INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
- (2020) Maria Carmela Pera et al. PLoS One
- SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
- (2019) Astrid Pechmann et al. Orphanet Journal of Rare Diseases
- Newborn screening for SMA in Southern Belgium
- (2019) François BOEMER et al. NEUROMUSCULAR DISORDERS
- Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1
- (2019) Omar Dabbous et al. ADVANCES IN THERAPY
- NFL is a marker of treatment response in children with SMA treated with nusinersen
- (2019) Bob Olsson et al. JOURNAL OF NEUROLOGY
- Impact of age and motor function in a phase 1/2A study of infants with SMA Type 1 receiving single-dose gene replacement therapy
- (2019) Linda P. Lowes et al. PEDIATRIC NEUROLOGY
- Neurofilament as a potential biomarker for spinal muscular atrophy
- (2019) Basil T. Darras et al. Annals of Clinical and Translational Neurology
- Nusinersen in type 1 spinal muscular atrophy: Twelve‐month real‐world data
- (2019) Marika Pane et al. ANNALS OF NEUROLOGY
- High-throughput genetic newborn screening for spinal muscular atrophy by rapid nucleic acid extraction from dried blood spots and 384-well qPCR
- (2019) Ludwig Czibere et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Fast skeletal muscle troponin activator CK‐2066260 increases fatigue resistance by reducing the energetic cost of muscle contraction
- (2019) Arthur J. Cheng et al. JOURNAL OF PHYSIOLOGY-LONDON
- Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
- (2019) Darryl C. De Vivo et al. NEUROMUSCULAR DISORDERS
- Development of an academic disease registry for spinal muscular atrophy
- (2019) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy
- (2019) Didu S. T. Kariyawasam et al. Frontiers in Neurology
- Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen
- (2019) Andreas Totzeck et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- P.352Interim report on the safety and efficacy of longer-term treatment with nusinersen in later-onset spinal muscular atrophy (SMA): results from the SHINE study
- (2019) J. Kirschner et al. NEUROMUSCULAR DISORDERS
- P.353FIREFISH Part 1: 16-month safety and exploratory outcomes of risdiplam (RG7916) treatment in infants with type 1 spinal muscular atrophy
- (2019) G. Baranello et al. NEUROMUSCULAR DISORDERS
- Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives
- (2019) Tamara Dangouloff et al. Therapeutics and Clinical Risk Management
- A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy
- (2019) Sonia Messina et al. NEUROMUSCULAR DISORDERS
- Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN
- (2018) Christian Hinderer et al. HUMAN GENE THERAPY
- Nusinersen for SMA: expanded access programme
- (2018) Michelle A Farrar et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Autophagy inhibition: a new therapeutic target in spinal muscular atrophy
- (2018) Antonio Piras et al. Neural Regeneration Research
- Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics
- (2018) Richard S. Finkel et al. NEUROMUSCULAR DISORDERS
- Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases
- (2018) Maite Calucho et al. NEUROMUSCULAR DISORDERS
- Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care
- (2018) Eugenio Mercuri et al. NEUROMUSCULAR DISORDERS
- Nusinersen in type 1 SMA infants, children and young adults: Preliminary results on motor function
- (2018) Marika Pane et al. NEUROMUSCULAR DISORDERS
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy
- (2018) Eugenio Mercuri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increasing Agrin Function Antagonizes Muscle Atrophy and Motor Impairment in Spinal Muscular Atrophy
- (2018) Marina Boido et al. Frontiers in Cellular Neuroscience
- Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)
- (2018) Hasane Ratni et al. JOURNAL OF MEDICINAL CHEMISTRY
- Nusinersen in spinal muscular atrophy type 1 patients older than 7 months
- (2018) Karolina Aragon-Gawinska et al. NEUROLOGY
- Pharmacological c-Jun NH2-Terminal Kinase (JNK) Pathway Inhibition Reduces Severity of Spinal Muscular Atrophy Disease in Mice
- (2018) Roberta Schellino et al. Frontiers in Molecular Neuroscience
- New Directions for SMA Therapy
- (2018) Sonia Messina Journal of Clinical Medicine
- A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier
- (2018) Stefan Sturm et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Pilot study of population-based newborn screening for spinal muscular atrophy in New York state
- (2017) Jennifer N Kraszewski et al. GENETICS IN MEDICINE
- Motor neuronal repletion of the NMJ organizer, Agrin, modulates the severity of the spinal muscular atrophy disease phenotype in model mice
- (2017) Jeong-Ki Kim et al. HUMAN MOLECULAR GENETICS
- Presymptomatic Diagnosis of Spinal Muscular Atrophy Through Newborn Screening
- (2017) Yin-Hsiu Chien et al. JOURNAL OF PEDIATRICS
- Regulation of Survival Motor Neuron Protein by the Nuclear Factor-Kappa B Pathway in Mouse Spinal Cord Motoneurons
- (2017) Saravanan Arumugam et al. MOLECULAR NEUROBIOLOGY
- CK-2127107 amplifies skeletal muscle response to nerve activation in humans
- (2017) Jinsy A. Andrews et al. MUSCLE & NERVE
- Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience
- (2017) Sonia Messina et al. NEUROMUSCULAR DISORDERS
- Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
- (2017) Jerry R. Mendell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
- (2017) Richard S. Finkel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature review
- (2017) Ingrid E. C. Verhaart et al. Orphanet Journal of Rare Diseases
- Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers
- (2017) Manaswini Sivaramakrishnan et al. Nature Communications
- Autophagy modulators regulate survival motor neuron protein stability in motoneurons
- (2016) Ambika Periyakaruppiah et al. EXPERIMENTAL NEUROLOGY
- Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset
- (2016) Zhihua Feng et al. HUMAN MOLECULAR GENETICS
- Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study
- (2016) Richard S Finkel et al. LANCET
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- Neuroprotective Effect of Non-viral Gene Therapy Treatment Based on Tetanus Toxin C-fragment in a Severe Mouse Model of Spinal Muscular Atrophy
- (2016) Sara Oliván et al. Frontiers in Molecular Neuroscience
- Genetic inhibition of JNK3 ameliorates spinal muscular atrophy
- (2015) Naresh K. Genabai et al. HUMAN MOLECULAR GENETICS
- Fast Skeletal Muscle Troponin Activator tirasemtiv Increases Muscle Function and Performance in the B6SJL-SOD1G93A ALS Mouse Model
- (2014) Darren T. Hwee et al. PLoS One
- How genetic modifiers influence the phenotype of spinal muscular atrophy and suggest future therapeutic approaches
- (2013) Brunhilde Wirth et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Survival motor neuron protein reduction deregulates autophagy in spinal cord motoneurons in vitro
- (2013) A Garcera et al. Cell Death & Disease
- Antisense-based therapy for the treatment of spinal muscular atrophy
- (2012) Frank Rigo et al. JOURNAL OF CELL BIOLOGY
- Pathophysiological Insights Derived by Natural History and Motor Function of Spinal Muscular Atrophy
- (2012) Michelle A. Farrar et al. JOURNAL OF PEDIATRICS
- Childhood spinal muscular atrophy: controversies and challenges
- (2012) Eugenio Mercuri et al. LANCET NEUROLOGY
- Spinal muscular atrophy: going beyond the motor neuron
- (2012) Gillian Hamilton et al. TRENDS IN MOLECULAR MEDICINE
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens
- (2011) Elaine A Sugarman et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Temporal requirement for high SMN expression in SMA mice
- (2011) T. T. Le et al. HUMAN MOLECULAR GENETICS
- The Canonical Nuclear Factor- B Pathway Regulates Cell Survival in a Developmental Model of Spinal Cord Motoneurons
- (2011) S. Mincheva et al. JOURNAL OF NEUROSCIENCE
- Spinal muscular atrophy
- (2011) Adele D'Amico et al. Orphanet Journal of Rare Diseases
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
- (2010) Y. Hua et al. GENES & DEVELOPMENT
- Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
- (2010) Kevin D Foust et al. NATURE BIOTECHNOLOGY
- Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
- (2010) C. F. Valori et al. Science Translational Medicine
- Survival motor Neuron protein regulates apoptosis in anin vitro model of Spinal muscular atrophy
- (2009) Graham C. Parker et al. NEUROTOXICITY RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now